Ocular Therapeutix Inc

NASDAQ:OCUL   3:58:52 PM EDT
18.74
+0.78 (+4.34%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.18B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$15.38 Million
Adjusted EPS-$0.08
See more estimates
10-Day MA$16.43
50-Day MA$11.59
200-Day MA$8.16
See more pivots

OCULAR THERAPEUTIX, INC Stock, NASDAQ:OCUL

15 CROSBY DRIVE, BEDFORD, MA 01730
United States of America
Phone: 781-895-3235
Number of Employees: 167

Description

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. The company's lead product includes DEXTENZA, which is in Phase III clinical trial for the treatment of post-surgical pain and inflammation, allergic conjunctivitis; and in Phase II clinical trial for the treatment of inflammatory dry eye disease. It is also developing OTX-TP, which is in Phase III clinical trial for glaucoma and ocular hypertension. In addition, the company has preclinical development of intravitreal depot with protein-based or small molecule drugs, including tyrosine kinase inhibitors, for the treatment of wet age-related macular degeneration and other retinal diseases. It has a strategic collaboration, option, and license agreement with Regeneron Pharmaceuticals, Inc. for the development of sustained release formulation of the vascular endothelial growth factor trap aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.